Is Vertex's plodding U.K. quibble coming to an end?
For the past two years, Vertex has been arguing with drug price watchdogs in the U.K. over the cost of one of its cystic fibrosis medicines, a protracted disagreement that has kept the treatment out of the hands of frustrated patients.
Now, as STAT's Ed Silverman reports, the two sides look closer than ever to a resolution. There was an eye-to-eye meeting, a promise to reconsider, and even a tweet of good faith.
But it's by no means a done deal, and the ongoing delay has left patients "incredibly frustrated," one group said.